Close Menu

NEW YORK – The US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded Cue Health a contract for $13 million to develop, validate, and obtain US regulatory clearance for a rapid molecular diagnostic test to detect SARS-CoV-2, the virus that causes COVID-19, the company said Tuesday.

The test is part of the Cue Health Monitoring System, a portable device that connects patients to a mobile health platform consisting of interventional components such as telemedicine consultations, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.